Peptide receptor radionuclide therapy (PRRT) is a molecular therapy which is also called radioisotope therapy. This type of therapy is used to treat a specific type of cancer called neuroendocrine tumors.
Global Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview
- Peptide receptor radionuclide therapy (PRRT) is a molecular therapy which is also called radioisotope therapy. This type of therapy is used to treat a specific type of cancer called neuroendocrine tumors.
Read Report Overview - https://www.transparencymarketresearch.com/peptide-receptor-radionuclide-therapy-prrt-market.html
- In peptide receptor radionuclide therapy, a targeting protein or peptide is combined with a small amount of radioactive material and injected into the patients’ bloodstream. This radiopeptide travels to and binds to neuroendocrine tumor cells, delivering a targeted high dose of radiation directly to the cancer cells.
- The global peptide receptor radionuclide therapy (PRRT) market is projected to expand at a significant pace during the forecast period, owing to increase in incidence of mainly gastro-entero-pancreatic
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76975
Key Drivers of Global Peptide Receptor Radionuclide Therapy (PRRT) Market
- Rise in awareness about effective use of peptide receptor radionuclide therapy is one of the important factors, which is likely to drive the market. Peptide receptor radionuclide therapy offers more personalized cancer treatment because radiopeptides are highly selective in their ability to specifically reach and damage neuroendocrine tumor cells, while limiting the radiation exposure. This has increased the global demand for usage as therapy in treating neuroendocrine cancers.
- Moreover, favorable reimbursement is likely to drive the market. Standard therapy with 177Lu-DOTATATE is approved by the FDA in the U.S. and by the EMA in the European Union.
Restraints of Global Peptide Receptor Radionuclide Therapy (PRRT) Market
- Supply of radioisotopes is unstable globally and is expected to reduce in the near future due to shut down of major reactors (Canada and the Netherlands)
- Short half-life radioisotopes cannot be supplied to other regions where the production of raw materials is negligible, as these disintegrate rapidly
- Moreover, several patients may experience nausea and vomiting after the administration of the peptide receptor radionuclide therapy. This is managed with anti-nausea medication or slowing down the administration of the amino acids. Long-term side effects can include a suppression of blood cell counts, which is mild to moderate in the majority of cases associated with the therapy. This is expected to hamper the growth of the market.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=76975
North America to Account for Major Share of Global Peptide Receptor Radionuclide Therapy (PRRT) Market
- Increase in access to health care, rise in incidence of cancer patients, and rapid introduction of advanced therapy and favourable reimbursement are some factors that likely to drive the market in North America
- Asia Pacific is expected to grow at significant rate, owing to growing demand for advancement treatment options and comparatively high prevalence of cancer in countries such as India, Taiwan, and China
Pre Book Peptide Receptor Radionuclide Therapy (PRRT) Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=76975<ype=S
Key Players Operating in Global Peptide Receptor Radionuclide Therapy (PRRT) Market
Major players operating in the global peptide receptor radionuclide therapy (PRRT) market are:
- Advanced Accelerator Applications SA (Novartis)
Browse more Reports by Transparency Market Research:
Pharmaceutical Contract Sales Outsourcing (CSO) Market: Significant expenditure on research & development and surge in number of pharmaceutical companies are the key factors projected to fuel the growth of the global pharmaceutical contract sales outsourcing (CSO) market during the forecast period.
FFPE Tissue Samples Market: FFPE is a form of preparation and preservation for biopsy specimens that helps in diagnostic/drug development, experimental research, and examination. A tissue sample is first fixed in formalin, also known as formaldehyde, to preserve vital structures and the proteins within the tissue. Subsequently, the tissue is embedded in a paraffin wax block; this helps for examination under a microscope. Significant applications of FFPE tissue samples is projected to boost the global FFPE tissue samples market from 2021 to 2031.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453